SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-17-139678
Filing Date
2017-04-26
Accepted
2017-04-26 16:57:02
Documents
6
Effectiveness Date
2017-04-26

Document Format Files

Seq Description Document Type Size
1 DEFA14A d294362ddefa14a.htm DEFA14A 38824
2 GRAPHIC g294362noticepg1.jpg GRAPHIC 2033
3 GRAPHIC g294362noticepg2a.jpg GRAPHIC 2041
4 GRAPHIC g294362noticepg2b.jpg GRAPHIC 2536
5 GRAPHIC g294362noticepg3.jpg GRAPHIC 2041
6 GRAPHIC g294362noticepg4.jpg GRAPHIC 2038
  Complete submission text file 0001193125-17-139678.txt   55280
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35347 | Film No.: 17785099
SIC: 2834 Pharmaceutical Preparations